High-profile gene editing startup Tome Biosciences said in a legal filing Friday that it will terminate virtually its entire staff beginning Nov. 1.
The Massachusetts WARN notice comes a day after STAT reported the company was in dire straits, with one source saying that it planned to wind down operations and seek a buyer by Nov. 1 after the company struggled to raise money or find a partner.
Tome told STAT it was only “operating at reduced capacity,” while “maintaining core expertise” as it “explore[d] strategic options.”
